Pre-market indicators show "BSEM stock price" at $13.08, with bid-ask spreads tightening. This often points to greater liquidity and potential intraday volatility, especially around news-sensitive biotech equities. Revenue: Increased to $41.9 million in Q1 2024 from $600,000 in Q1 2023. About BioStem Technologies, Inc. (OTC: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioREtain ® processing method. BioREtain ® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies’ quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (“AATB”). These systems and procedures are established per current Good Tissue Practices (“cGTP”) and current Good Manufacturing Processes (“cGMP”). Our portfolio of quality brands includes AmnioWrap2™, VENDAJE ® , VENDAJE AC ® , and VENDAJE OPTIC ® . Each BioStem Technologies placental allograft is processed at the Company’s FDA registered and AATB accredited site in Pompano Beach, Florida. For more information visit biostemtechnologies.com and follow us on X and LinkedIn . The "BSEM stock price" is trending sideways at $12.96, with RSI indicating neutral momentum. Technical traders are watching for a cross above the 50-day moving average, which could trigger a bullish signal in the biotech sector.
